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Rapid and scalable synthesis of innovative
unnatural α,β or γ-amino acids functionalized with
tertiary amines on their side-chains†
Séverine Schneider,a Hussein Ftouni,a Songlin Niu,a Martine Schmitt,a
Frédéric Simoninb and Frédéric Bihel*a
We report a selective ruthenium catalyzed reduction of tertiary amides on the side chain of Fmoc-Gln-
OtBu derivatives, leading to innovative unnatural α,β or γ-amino acids functionalized with tertiary amines.
Rapid and scalable, this process allowed us to build a library of basic unnatural amino acids at the gram-
scale and directly usable for liquid- or solid-phase peptide synthesis. The diversity of available tertiary
amines allows us to modulate the physicochemical properties of the resulting amino acids, such as basi-
city or hydrophobicity.
Introduction
Although peptides are the keystones of most vital processes,
only a few peptide-based drugs were marketed in the 20th
century. Among other criteria, low bioavailability and meta-
bolic instability led to a global rejection of peptides as drug
candidates by the pharmaceutical industry. However, in the
last decade, new therapeutic strategies were promoted, and
more than 100 peptide-based drugs have already reached the
market.1 In order to circumvent the inherent problems of bio-
availability and biostability of peptides, protein-like backbones
called peptidomimetics were developed in order to mimic
native peptides, but with better pharmacological properties.
Unnatural amino acids were then generated from natural
amino acids through chemical modifications of this backbone
(amine alkylation, backbone extension, cyclization or isosteric
replacements).2 Another great area of interest was the design
of “non-natural” side chains, allowing the improvement of
interactions between the peptide and its targeted protein.
Regarding this aspect, a large diversity of side chains were
developed, but non-natural amino acids bearing various aro-
matic side chains were more extensively reported.2d,3 In con-
trast, side chains bearing a basic amino group mimicking
ornithine, lysine or arginine derivatives were less well reported.
Most of the lysine analogs resulted from a reductive amination
between aldehydes and Fmoc-Lys-OH aﬀording monoalkylated
or symmetric dialkylated lysine derivatives.4 Through an alkyl-
ation of glycine in the solid-phase, Scott et al. reported an
interesting synthesis of non-natural racemic amino acids
bearing the pyrrolidine ring.5 Indeed, introduction of azacycles
through reductive amination is still challenging.6 For the first
time, we propose in this paper a versatile synthesis of non-
natural basic amino acids, bearing a high diversity of cyclic or
acyclic tertiary amines on the side chain. Protected by a Fmoc
group in the N-terminus, these new non-natural amino acids
are directly available for liquid or solid phase peptide synthesis.
Results and discussion
Metal-catalyzed reductions of carboxamides in combination
with silanes were extensively studied in recent years with
simple amides such as benzamide derivatives.7 Our challenge
was to look for the selective reduction of the amide function of
the glutamate derivative 1 (Table 1), bearing two other reduci-
ble groups (ester and carbamate) and one chiral center.
Starting from the commercially available Fmoc-L-Glu-OtBu,
piperidine was coupled on the side chain to aﬀord amide
derivative 1a in a quantitative yield. We next evaluated three
known catalytic systems (Table 1), involving Zn,7f Ir,7k or Ru,7r
for reduction of the carboxamide function in a selective
manner towards both urethane (Fmoc) and tert-butyl ester
functions. As compound 1a was poorly soluble in toluene, THF
was preferred as the solvent. Zinc-mediated reduction was not
observed (entry 1), whereas [Ir(COD)Cl]2 and Ru3(CO)12 in
combination with Et2SiH2 or tetramethyldisiloxane (TMDS)
produced amine 2a in high yields at only 40 °C (entries
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2–4 and 7). As the main goal of this study was to propose a
gram-scale synthesis of non-natural basic amino acids, the
catalytic system Ru3(CO)12/TMDS was selected as it is cheaper
than the system associated with an iridium-based catalyst and
Et2SiH2. In 2013, Reeves et al. reported that 1% Ru3(CO)12 in
the presence of 4 eq. of TMDS at 50 °C in toluene was eﬃcient
enough to reduce a large set of amides.7r In our case, the
reduction of the glutamine derivative 1a required at least
3 mol% of the catalyst in THF at 40 °C (Table 1, compare
entries 7 & 8). Easy to handle, the reaction was carried out
under air. The key-step of this procedure appeared to be the
purification stage. Indeed, after the completion of the
reduction step, the resulting tert-butyl ester was recovered in
poor yields (<30%) after normal or reversed phase chromato-
graphy, although no side product was observed. A treatment of
this tert-butyl ester with trifluoroacetic acid aﬀorded com-
pound 2a as a TFA salt. Precipitation in ether of this salt led to
medium yield (≈50%). Subsequently, the trifluoroacetate
counter-ion was exchanged with HCl 1 M in diethyl ether,
aﬀording a white precipitate 2a as a hydrochloride salt in 81%
yield. As the optimization step was performed on a 100 mg
scale, we next extended the scope of the reaction to the gram-
scale with a large set of tertiary amines (Table 2). Under these
conditions, compounds 2 were globally obtained in good to
excellent yields after precipitation in ether. The reaction was
compatible with the hindered amine (2d) and allowed the
introduction of other chiral centers (2c, 2d). Several functional
groups were tolerated, such as tertiary amines (2e, 2g), 2-amino-
pyrimidine (2f ), ester (2h), and alcohol (2i). A series of
amines bearing an aromatic ring was also easily synthesized
(2j–o). Although aniline derivatives were well tolerated (2l, 2n),
benzimidazole derivative 2m was not recovered as its precursor
amide 1m was poorly stable. Acyclic amines (2n–q) were also
easily obtained in high yields. Interestingly, after coupling the
Bn-NH-NH-Boc on Fmoc-L-Glu-OtBu, we were able to reduce
the hydrazide function to produce the corresponding hydra-
zine derivative 2r as a non-natural analog of lysine. In spite of
the protonated state of the terminal amine, Fmoc cleavage was
observed, explaining the modest yield of 30% for compound
2r. With yields inferior to 80%, compounds 2g, 2h, and 2r
were purified by flash chromatography to remove the bypro-
ducts. All the other compounds were easily recovered after pre-
cipitation with purity higher than 98%. Starting from Fmoc-L-
Asp-OtBu, we were able to obtain compound 4, exhibiting a
shorter side-chain than 2a. Next, we explored the possibility of
reducing the carboxamide function on the backbone. Starting
from commercially available Fmoc-L-Asp(OtBu)-OH or Fmoc-L-
Glu(OtBu)-OH, piperidine was coupled to the C-terminus part
to aﬀord compounds 5 and 6. Ruthenium-based reduction of
the resulting carboxamide led to the β,γ-diamino acid 7 and
the γ,δ-diamino acid 8 in excellent yields (Scheme 1).
Table 1 Optimization of the reaction conditionsa
Entry Catalyst Mol% Silane Equiv. Yieldb (%)
1 Zn(OAc)2 3 (EtO)3SiH 8 0
2 [Ir(COD)Cl]2 3 Et2SiH2 8 74
3 [Ir(COD)Cl]2 3 TMDS 8 59
4 Ru3(CO)12 3 Et2SiH2 8 74
5 Ru3(CO)12 3 (EtO)3SiH 8 60
6 Ru3(CO)12 3 iPr3SiH 8 0
7 Ru3(CO)12 3 TMDS 8 80
8 Ru3(CO)12 1 TMDS 8 40
9 Ru3(CO)12 5 TMDS 8 80
10 Ru3(CO)12 3 TMDS 2 60
11 Ru3(CO)12 3 TMDS 4 78
12 Ru3(CO)12 3 TMDS 6 81
a Reaction conditions: (1) 1a (0.2 mmol), catalyst, silane, THF (1 mL),
40 °C, 16 h; (2) TFA/DCM (v : v – 2 mL); (3) HCl 1 N in ether (5 mL).
bDetermined by HPLC using caﬀeine as external standard.
Table 2 Building of a library of α-amino acids functionalized with a
large diversity of tertiary aminesa
a Reaction conditions: (1) 1 (2 mmol), Ru3(CO)12 (5 mol%), TMDS
(16 mmol), THF (10 mL), 40 °C, 16 h; (2) TFA/DCM (v : v – 20 mL); (3)
HCl 1 N in ether (30 mL). b Yield after column chromatography.
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The absence of the need for purification by chromatography
allowed us to easily produce large quantity of these unnatural
amino acids, with 98% minimum purity measured by HPLC
and NMR. However, neither of these analytical techniques
allows the detection of ruthenium. Using ICP-mass spectro-
metry, we were able to quantify 2.1% (w/w) of ruthenium
after final precipitation. Using resin-bound dimercaptotriazine
as a scavenger in a solution of 2a in a mixture of DCM/MeOH
[9 : 1], we were able to remove up to 90% of the ruthenium,
leading to a final 0.2% (w/w) of residual ruthenium. We next
evaluated whether this whole synthetic procedure may induce
racemization of the Cα of the amino acids formed. To answer
this question, both enantiomers L-2a and D-2a were coupled
to H-L-Phe-NH2 using several standard coupling reagents (BOP,
COMU, HATU). By using HPLC, we were able to evaluate the
racemization ratio as lower than 1% (ESI†). By repeating this
last coupling reaction, we determined that the resulting traces
of racemization were occurring during the coupling reaction
with H-Phe-NH2, and not during the reductive process.
This very eﬃcient synthesis allows a rapid and scalable
access to a large variety of unnatural N-Fmoc α-, β- or γ-amino
acids. These residues can be easily introduced into the peptide
sequence as mimetics of natural basic amino acids such as
ornithine, lysine or arginine. However, these new unnatural
amino acids give access to a larger range of basicity and hydro-
phobicity, depending on the tertiary amine chosen on the side
chain. To highlight this concept, we compared the hydro-
phobicity (logD) and the basicity (pKa) for the 20 unnatural amino
acids synthesized in this paper and compared them with
ornithine, lysine and arginine (Chart 1). To be as close as poss-
ible to a peptide structure, calculations were performed with
each amino acid under the form Ac-Xaa-NH-Me. Ornithine,
lysine and arginine form a very hydrophilic cluster (logD < −4)
with basicity ranging from 9.6 to 11.2. In contrast, the 20 un-
natural amino acids show extended ranges of log D (from −3.4
to +0.5) and pKa (from 4.7 to 10.3). By introducing these un-
natural amino acids into peptide sequences in replacement of
basic amino acids such as lysine, ornithine or arginine, we will
be able to modulate the physicochemical properties of the
resulting peptidomimetics. A first application for these novel
non-natural basic amino acids was demonstrated in a liquid-
phase synthesis of compounds 9a and 9b (Scheme 2), which
were recently reported as the first orally active antagonists of
NPFF receptors to prevent opioid-induced hyperalgesia in
rodents.9 Starting from compounds 2a and 2j, compounds 9a
and 9b were easily synthesized using standard peptide syn-
thesis. This new strategy appears to be much more eﬃcient
and less time-consuming than the previously reported
method.9 More importantly, the availability of the building
block 2 allows a fast optimization of the N- and C-terminus in
a convergent manner, which is not possible with the reported
synthesis.9 Compounds 9 were initially developed as a peptido-
mimetic of the corresponding arginine residue.9 Using stan-
dard solid-phase synthesis, we pushed the concept further by
replacing the arginine moiety of the neuropeptide FF by the
residue 2j in order to generate a peptidomimetic analog of the
peptide NPFF (Fig. 1). Using 2j immediately after precipitation
in ether and using the Fmoc-strategy on a Rink-amide resin,
we were able to synthesize peptide 10 with a good purity by
HPLC after cleavage. The analysis of the crude peptide by
ICP-MS led us to quantify the residual ruthenium as less than
20 ppm. Aﬃnities of 10 for both NPFF1 and NPFF2 receptors
were measured and compared to the endogenous peptide
NPFF. Although showing lower aﬃnities than NPFF,10 com-
pound 10 still shows a significant aﬃnity for NPFF2R, but
binds poorly to NPFF1R. These results highlight how these
Scheme 1 Ru-catalyzed synthesis of nor-ornithine analogs and β,γ and
γ,δ-diamino acids.
Chart 1 LogD7.4 and pKa for Ac-Xaa-NHMe. Calculator plugin (Marvin
6.0.2, 2013, http://www.chemaxon.com). LogD was predicted at a pH
7.4 following the method reported by Klopman et al.8
Scheme 2 Application of the non-natural amino acid 2a to the syn-
thesis of 9, an orally-active antagonist of opioid-induced hyperalgesia.
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new basic amino acids can be used to generate peptidomi-
metics with interesting pharmacological profiles.
Conclusion
We have reported an eﬃcient and selective metal-catalyzed
amide reduction allowing the rapid production at the gram-
scale, of original unnatural basic α-, β- or γ-amino acids,
readily available for liquid- or solid-phase peptide synthesis.
These new amino acids will constitute important building
blocks for the synthesis of future peptidomimetics. The versa-
tility of the process allows the introduction of a very large
diversity of basic tertiary amines exhibiting various physico-
chemical properties, potentially oﬀering a wide spectrum of
uses (cell-penetrating peptide, peptidomimetic, etc.).
Experimental
General procedure for the reduction of amides into the
corresponding amines 2
TMDS (6.5 mL, 35.7 mmol, 8 equiv.) was added to Ru3(CO)12
(0.144 g, 0.223 mmol, 0.05 equiv.) under air. The mixture was
stirred for 5 minutes, then a solution of compound 1
(4.46 mmol, 1 equiv.) in 24 mL of THF was added, and the
reaction mixture was stirred for 16 hours under air at 40 °C.
Volatiles were removed in vacuo. The reaction mixture was
diluted with DCM (24 mL), and cooled to 0 °C in an ice bath.
Trifluoroacetic acid (20 mL) was slowly added at 0 °C. After
addition, the reaction mixture was stirred at room temperature
for 4 hours. Volatiles were removed under reduced pressure,
and the resulting mixture was diluted in diethyl ether (10 mL).
A solution of HCl (1 M) in diethyl ether (48 mL) was slowly
added to the mixture, and the reaction mixture was stirred at
room temperature for 5 minutes, aﬀording a white powder
after filtration. The powder was next solubilized in DCM with
10% MeOH. To remove residual ruthenium, dimercaptotri-
azine on silica (SiliaBond DMT from Silicycle, 0.5 mmol g−1 of
resin, 1.8 mmol) was added and the mixture was stirred for 1 h
at room temperature, and filtered and rinsed with DCM. Com-
pounds 2 were recovered after evaporation and lyophilization.
Only compounds 2g, 2h and 2r were required to be purified by
chromatography using a reversed-phase C18 column.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(piper-
idin-1-yl)pentanoic acid hydrochloride (L-2a). 98% yield; [α]20D =
−10.5 (c = 0.5 in DMF); 1H NMR (DMSO-d6, 400 MHz): δ = 7.90
(d, J = 7.5 Hz, 2H), 7.72 (m, 2H), 7.42 (dd, J = 7.5, 7.5 Hz, 2H),
7.33 (dd, J = 7.5, 7.5 Hz, 2H), 4.34–4.21 (m, 3H), 3.97 (td, J =
3.1, 8.6 Hz, 1H), 3.35 (m, 2H), 2.97 (m, 2H), 2.80 (m, 2H),
1.83–1.61 (m, 9H), 1.44–1.30 (m, 1H); 13C NMR (DMSO-d6,
100 MHz): δ = 173.9, 156.7, 144.3, 141.2, 128.1, 127.6, 125.7,
120.6, 66.1, 55.8, 53.8, 52.6, 52.3, 47.1, 28.5, 22.8, 21.8, 20.6;
HRMS (ESI+) calcd for C25H30N2O4 [M + H]
+ 423.2278, found
423.2278.
(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(piper-
idin-1-yl)pentanoic acid hydrochloride (D-2a). 79% yield;
[α]20D = +11.5 (c = 0.5 in DMF);
1H NMR (DMSO-d6, 400 MHz):
δ = 7.90 (d, J = 7.5 Hz, 2H), 7.72 (m, 2H), 7.42 (dd, J = 7.5, 7.5
Hz, 2H), 7.33 (dd, J = 7.5, 7.5 Hz, 2H), 4.34–4.21 (m, 3H), 3.97
(td, J = 3.1, 8.6 Hz, 1H), 3.35 (m, 2H), 2.97 (m, 2H), 2.80
(m, 2H), 1.83–1.61 (m, 9H), 1.44–1.30 (m, 1H); 13C NMR (DMSO-d6,
100 MHz): δ = 173.9, 156.7, 144.3, 141.2, 128.1, 127.6, 125.7,
120.6, 66.1, 55.8, 53.8, 52.6, 52.3, 47.1, 28.5, 22.8, 21.8, 20.6;
HRMS (ESI+) calcd for C25H30N2O4 [M + H]
+ 423.2278, found
423.2278.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(azepan-
1-yl)pentanoic acid hydrochloride (2b). 93% yield; [α]20D = −9.5
(c = 1.0 in DMF); 1H NMR (DMSO-d6, 400 MHz): δ = 7.90 (d, J =
7.5 Hz, 2H), 7.73 (d, J = 7.5 Hz, 1H), 7.71 (d, J = 7.5 Hz, 1H),
7.42 (dd, J = 7.5, 7.5 Hz, 2H), 7.34 (dd, J = 7.5, 7.5 Hz, 2H),
4.34–4.21 (m, 3H), 3.97 (m, 1H), 3.25–3.12 (m, 2H), 3.12–2.94
(m, 4H), 1.93–1.70 (m, 6H), 1.69–1.50 (m, 6H); 13C NMR
(DMSO-d6, 100 MHz): δ = 173.3, 156.1, 143.7, 140.6, 127.6,
127.0, 125.2, 120.1, 65.6, 55.6, 53.3, 46.6, 27.9, 26.0, 22.8, 20.4;
HRMS (ESI+) calcd for C26H32N2O4 [M + H]
+ 437.2435, found
437.2438.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-((R)-2-
methylpyrrolidin-1-yl)pentanoic acid hydrochloride (2c). 96%
yield; [α]20D = −26.2 (c = 0.5 in DMF); 1H NMR (DMSO-d6,
400 MHz): δ = 7.89 (d, J = 7.5 Hz, 2H), 7.73 (m, 2H), 7.42 (dd,
J = 7.5, 7.5 Hz, 2H), 7.34 (dd, J = 7.5, 7.5 Hz, 2H), 4.29 (m, 2H),
4.24 (m, 1H), 3.98 (m, 1H), 3.54 (m, 1H), 3.23 (m, 1H), 2.98
(m, 1H), 2.87 (m, 1H), 2.14 (m, 1H), 1.90 (m, 3H), 1.81–1.55
(m, 5H), 1.36 (d, J = 6.4 Hz, 3H); 13C NMR (DMSO-d6,
100 MHz): δ = 173.4, 156.2, 143.8, 140.6, 127.6, 127.1, 125.2,
120.1, 65.7, 63.4, 53.3, 52.2, 51.3, 46.6, 30.8, 27.9, 21.6, 20.8,
15.1; HRMS (ESI+) calcd for C25H30N2O4 [M + H]
+ 423.2278,
found 423.2271.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-((1S,5R)-
1-methyl-6-azabicyclo[3.2.1]octan-6-yl)pentanoic acid hydro-
chloride (2d). 86% yield; [α]20D = −9.7 (c = 0.5 in DMF);
1H NMR (MeOD-d4, 400 MHz): δ = 7.80 (d, J = 7.5 Hz, 2H), 7.67
(m, 2H), 7.40 (dd, J = 7.5 Hz, 2H), 7.32 (dd, J = 7.5 Hz, 2H),
4.41 (m, 1H), 4.32 (m, 1H), 4.23 (m, 2H), 3.90 (m, 1H), 3.72
(dd, J = 48.4, 12.4 Hz, 1H), 3.20 (m, 2H), 2.88–2.73 (m, 1H),
2.08–1.52 (m, 10H), 1.22–0.96 (m, 9H); 13C NMR (MeOD-d4,
125 MHz): δ = 175.2, 158.9, 145.4, 145.2, 142.7, 129.0, 128.4,
126.3, 121.1, 69.0, 68.6, 68.2, 67.0, 64.0, 63.6, 59.0, 54.8, 54.4,
51.6, 48.5, 42.5, 42.4, 42.0, 40.1, 37.1, 33.0, 29.9, 29.7, 29.5,
Fig. 1 Application of the non-natural amino acid 2j to the synthesis of
an unnatural analog of the endogenous neuropeptide NPFF 10.
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24.9, 22.9, 22.7, 15.6; HRMS (ESI+) calcd for C30H38N2O4
[M + H]+ 491.2904, found 437.2895.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(4-methyl-
piperazin-1-yl)pentanoic acid hydrochloride (2e). 85% yield;
[α]20D = −7.3 (c = 0.5 in DMF); 1H NMR (DMSO-d6, 400 MHz):
δ = 8.52 (s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.73 (d, J = 7.5 Hz, 1H),
7.71 (d, J = 7.5 Hz, 1H), 7.42 (dd, J = 7.5, 7.5 Hz, 2H), 7.34 (dd,
J = 7.5, 7.5 Hz, 2H), 4.34–4.19 (m, 3H), 3.96 (m, 1H), 3.75–3.59
(m, 4H), 3.54–3.30 (m, 4H), 3.24–3.05 (m, 2H), 2.81 (s, 3H),
1.95–1.60 (m, 4H); 13C NMR (DMSO-d6, 100 MHz): δ = 173.3,
156.1, 143.7, 140.6, 127.6, 127.1, 125.2, 120.1, 65.6, 53.4, 51.2,
49.5, 47.9, 46.6, 27.8, 20.1; HRMS (ESI+) calcd for C25H31N3O4
[M + H]+ 438.2387, found 438.2395.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(4-(pyri-
midin-2-yl)piperazin-1-yl)pentanoic acid hydrochloride
(2f). 98% yield; [α]20D = −6.3 (c = 1.8 in DMF); 1H NMR (MeOD-
d4, 400 MHz): δ = 8.54 (d, J = 5.2 Hz, 2H), 7.80 (d, J = 7.6 Hz,
2H), 7.68 (d, J = 7.6 Hz, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.40 (dd,
J = 7.6 Hz, 2H), 7.35–7.29 (m, 2H), 6.93 (dd, J = 5.2 Hz, 1H),
4.84 (m, 2H), 4.41 (m, 1H), 4.34 (m, 1H), 4.23 (m, 2H),
3.76–3.63 (m, 2H), 3.63–3.46 (m, 2H), 3.28–3.10 (m, 4H),
2.02–1.70 (m, 4H); 13C NMR (MeOD-d4, 100 MHz): δ = 175.1,
158.9, 158.6, 145.4, 142.7, 128.9, 128.3, 126.3, 121.1, 112.6,
68.2, 57.7, 54.7, 52.5, 42.7, 29.8, 21.9; HRMS (ESI+) calcd for
C28H31N5O4 [M + H]
+ 502.2449, found 502.2458.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-([1,4′-
bipiperidin]-1′-yl)pentanoic acid hydrochloride (2g). 61%
yield after column chromatography; [α]20D = −6.3 (c = 0.5 in
DMF); 1H NMR (DMSO-d6, 400 MHz): δ = 7.89 (d, J = 7.5 Hz,
2H), 7.73 (d, J = 7.5 Hz, 1H), 7.65 (d, J = 7.5 Hz, 1H), 7.42 (dd,
J = 7.5 Hz, 2H), 7.33 (dd, J = 7.5 Hz, 2H), 4.33–4.18 (m, 3H),
3.95 (m, 1H), 2.99 (m, 5H), 2.53 (m, 4H), 2.20 (m, 2H),
1.89–2.05 (m, 2H), 1.78–1.43 (m, 12H); 13C NMR (DMSO-d6,
100 MHz): δ = 173.7, 156.1, 143.7, 140.7, 127.6, 127.0, 125.2,
120.1, 65.6, 56.0, 53.6, 51.2, 49.1, 46.6, 28.5, 25.1, 23.3, 22.1,
22.0; HRMS (ESI+) calcd for C30H39N3O4 [M + H]
+ 506.3013,
found 506.3010.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(4-(ethoxy-
carbonyl)piperidin-1-yl)pentanoic acid hydrochloride (2h). 58%
yield after column chromatography; [α]20D = −7.3 (c = 0.5 in
DMF); 1H NMR (MeOD-d4, 400 MHz): δ = 7.78 (d, J = 7.5 Hz,
2H), 7.66 (d, J = 7.5 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.38 (dd,
J = 7.5 Hz, 2H), 7.30 (dd, J = 7.5 Hz, 2H), 4.36 (m, 2H), 4.19 (t,
J = 6.6 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 4.01 (m, 1H), 3.56–3.33
(m, 2H), 3.08–2.76 (m, 4H), 2.60 (m, 1H), 2.16–2.04 (m, 2H),
2.03–1.87 (m, 2H), 1.83–1.45 (m, 4H), 1.21 (t, J = 7.1 Hz, 3H);
13C NMR (MeOD-d4, 100 MHz): δ = 178.4, 174.7, 158.1, 145.6,
142.7, 128.9, 128.3, 126.3, 121.1, 67.8, 62.1, 57.8, 56.8, 52.3,
48.6, 31.1, 26.5, 21.5, 14.6; HRMS (ESI+) calcd for C28H34N2O6
[M + H]+ 495.2490, found 495.2502.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(4-hydroxy-
piperidin-1-yl)pentanoic acid hydrochloride (2i). 96% yield;
[α]20D = −8.3 (c = 0.5 in DMF); 1H NMR (MeOD-d4, 400 MHz):
δ = 7.79 (d, J = 7.5 Hz, 2H), 7.66 (d, J = 7.5 Hz, 1H), 7.64 (d, J =
7.5 Hz, 1H), 7.38 (dd, J = 7.5 Hz, 2H), 7.30 (dd, J = 7.5 Hz, 2H),
4.37 (m, 2H), 4.20 (t, J = 6.6 Hz, 1H), 4.01 (m, 1H), 3.89 (m, 1H),
3.40–3.21 (m, 2H), 3.18–2.79 (m, 4H), 2.01 (m, 2H), 1.91–1.59
(m, 6H); 13C NMR (MeOD-d4, 100 MHz): δ = 178.4, 158.1,
145.5, 142.7, 128.9, 128.3, 126.3, 121.1, 67.7, 57.7, 56.9, 48.6,
31.9, 31.2, 21.6; HRMS (ESI+) calcd for C25H30N2O5 [M + H]
+
439.2227, found 439.2236.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(4-benzyl-
piperidin-1-yl)pentanoic acid hydrochloride (2j). 93% yield;
[α]20D = −8.3 (c = 0.5 in DMF); 1H NMR (MeOD-d4, 400 MHz):
δ = 7.78 (d, J = 7.5 Hz, 2H), 7.67 (d, J = 7.5 Hz, 1H), 7.65 (d, J =
7.5 Hz, 1H), 7.38 (dd, J = 7.5 Hz, 2H), 7.34–7.24 (m, 4H),
7.22–7.13 (m, 3H), 4.40 (dd, J = 10.8, 6.5 Hz, 1H), 4.31 (m, 1H),
4.21 (m, 2H), 3.48 (d, J = 11.4 Hz, 2H), 3.07 (m, 2H), 2.84 (m,
2H), 2.58 (d, J = 6.5 Hz, 2H), 1.96–1.72 (m, 7H), 1.50 (m, 2H);
13C NMR (MeOD-d4, 100 MHz): δ = 175.0, 158.8, 145.4, 142.7,
140.5, 130.3, 129.6, 128.9, 128.3, 127.5, 126.3, 121.1, 68. 1,
57.7, 54.6, 54.3, 48.4, 43.1, 36.8, 30.6, 29.8, 21.9; HRMS (ESI+)
calcd for C32H36N2O4 [M + H]
+ 513.2748, found 513.2749.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(3,4-
dihydroisoquinolin-2(1H)-yl)pentanoic acid hydrochloride
(2k). 92% yield; [α]20D = −7.9 (c = 0.8 in DMF); 1H NMR (DMSO-
d6, 400 MHz): δ = 7.90 (d, J = 7.5 Hz, 2H), 7.74 (d, J = 7.5 Hz,
1H), 7.73 (d, J = 7.5 Hz, 1H), 7.42 (dd, J = 7.5 Hz, 2H), 7.34 (dd,
J = 7.5 Hz, 2H), 7.30–7.21 (m, 3H), 7.18 (m, 1H), 4.48 (m, 1H),
4.38–4.19 (m, 4H), 4.01 (m, 1H), 3.64 (m, 1H), 3.34–3.13 (m,
4H), 3.01 (m, 1H), 1.94–1.63 (m, 4H); 13C NMR (MeOD-d4,
100 MHz): δ = 173.6, 156.4, 144.0, 141.0, 131.7, 128.8, 127.9,
127.4, 126.9, 125.5, 120.4, 66.0, 54.8, 53.6, 51.9, 48.9, 46.9,
28.2, 25.0, 20.7; HRMS (ESI+) calcd for C29H30N2O4 [M + H]
+
471.2278, found 471.2293.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(indolin-
1-yl)pentanoic acid hydrochloride (2l). 94% yield; [α]20D = +2.1
(c = 0.6 in MeOH); 1H NMR (MeOD-d4, 400 MHz): δ = 7.76 (d,
J = 7.5 Hz, 2H), 7.64 (d, J = 7.5 Hz, 1H), 7.61 (d, J = 7.5 Hz, 1H),
7.52–7.40 (m, 4H), 7.34 (dd, J = 7.5 Hz, 2H), 7.26 (dd, J =
7.5 Hz, 2H), 4.32 (m, 2H), 4.18 (m, 2H), 3.91 (m, 2H), 3.56
(m, 2H), 2.17–1.67 (m, 6H); 13C NMR (DMSO-d6, 100 MHz): δ =
173.5, 156.0, 143.6, 140.5, 127.5, 126.9, 125.1, 120.0, 65.5, 53.3,
52.4, 46.5, 28.0, 27.7, 22.1; HRMS (ESI+) calcd for C28H28N2O4
[M + H]+ 457.2122, found 457.2136.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl-
(phenyl)amino)pentanoic acid hydrochloride (2n). 98% yield;
[α]20D = −7.2 (c = 1.2 in DMF); 1H NMR (MeOD-d4, 400 MHz):
δ = 7.72 (d, J = 7.5 Hz, 1H), 7.71 (d, J = 7.5 Hz, 1H), 7.59 (dd, J =
7.5 Hz, 2H), 7.31 (dd, J = 7.5 Hz, 2H), 7.19–7.25 (m, 2H), 7.11
(dd, J = 7.5 Hz, 2H), 6.69 (d, J = 8.0 Hz, 2H), 6.59 (dd, J =
7.5 Hz, 1H), 4.30 (m, 2H), 4.13 (m, 2H), 3.27 (m, 2H), 2.83
(s, 3H), 1.82 (m, 1H), 1.60 (m, 3H); 13C NMR (MeOD-d4,
100 MHz): δ = 176.0, 158.7, 150.7, 145.3, 142.7, 130.2, 128.9,
128.3, 126.3, 121.0, 117.9, 114.1, 68.0, 55.3, 53.5, 48.6, 38.9,
30.4, 24.1; HRMS (ESI+) calcd for C27H28N2O4 [M + H]
+
445.2122, found 445.2126.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(methyl-
(phenethyl)amino)pentanoic acid hydrochloride (2o). 96%
yield; [α]20D = −8.5 (c = 0.8 in DMF); 1H NMR (MeOD-d4,
400 MHz): δ = 7.79 (d, J = 7.5 Hz, 2H), 7.67 (d, J = 7.5 Hz, 1H),
7.65 (d, J = 7.5 Hz, 1H), 7.39 (dd, J = 7.5 Hz, 2H), 7.35–7.23
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(m, 7H), 4.42 (dd, J = 10.1, 6.6 Hz, 1H), 4.33 (m, 1H), 4.22
(m, 2H), 3.38 (m, 2H), 3.22 (m, 2H), 3.06 (m, 2H), 2.91 (s, 3H),
1.96 (m, 1H), 1.90–1.70 (m, 3H); 13C NMR (DMSO-d6,
100 MHz): δ = 173.9, 156.7, 144.2, 141.2, 137.5, 129.2, 129.1,
128.1, 127.6, 127.3, 125.7, 120.6, 66.2, 56.3, 54.8, 53.9, 47.1,
29.8, 28.3, 20.6; HRMS (ESI+) calcd for C29H32N2O4 [M + H]
+
473.2435, found 473.2448.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(butyl-
(methyl)amino)pentanoic acid hydrochloride (2p). 98% yield;
[α]20D = −9.9 (c = 1.4 in DMF); 1H NMR (MeOD-d4, 400 MHz):
δ = 7.79 (d, J = 7.5 Hz, 2H), 7.68 (d, J = 7.5 Hz, 1H), 7.66 (d, J =
7.5 Hz, 1H), 7.39 (dd, J = 7.5 Hz, 2H), 7.31 (dd, J = 7.5 Hz, 2H),
4.41 (dd, J = 10.3, 6.7 Hz, 1H), 4.33 (m, 1H), 4.22 (m, 2H),
3.22–3.00 (m, 4H), 2.82 (s, 3H), 2.12–1.59 (m, 6H), 1.38 (m,
2H), 0.97 (t, J = 7.4 Hz, 3H); 13C NMR (MeOD-d4, 100 MHz): δ =
175.1, 158.9, 145.4, 142.7, 129.0, 128.3, 126.3, 121.1, 68.2, 57.5,
56.8, 54.7, 40.8, 29.8, 27.3, 22.0, 21.0, 14.0; HRMS (ESI+) calcd
for C25H32N2O4 [M + H]
+ 425.2435, found 425.2453.
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-((2-cyano-
ethyl)(methyl)amino)pentanoic acid hydrochloride (2q). 89%
yield; [α]20D = −7.9 (c = 0.5 in DMF); 1H NMR (MeOD-d4,
400 MHz): δ = 7.79 (d, J = 7.5 Hz, 2H), 7.66 (d, J = 7.5 Hz, 1H),
7.65 (d, J = 7.5 Hz, 1H), 7.38 (dd, J = 7.5 Hz, 2H), 7.30 (dd, J =
7.5 Hz, 2H), 4.38 (m, 2H), 4.21 (t, J = 6.7 Hz, 1H), 4.07 (m, 1H),
3.07 (t, J = 7.0 Hz, 2H), 2.80 (m, 4H), 2.54 (s, 3H), 1.90–1.54 (m,
4H); 13C NMR (MeOD-d4, 100 MHz): δ = 177.5, 158.5, 145.5,
142.7, 128.9, 128.3, 126.3, 121.1, 119.1, 67.9, 57.5, 56.1, 53.0,
48.6, 41.0, 30.8, 23.1, 15.0; HRMS (ESI+) calcd for C24H27N3O4
[M + H]+ 422.2074, found 422.2080.
(2S)-5-(1-Benzylhydrazin-1-yl)-2-{[(9H-fluoren-9-ylmethoxy)-
carbonyl]amino}pentanoic acid hydrochloride (2r). 30% yield
after column chromatography; [α]20D = −7.3 (c = 0.9 in DMF);
1H NMR (MeOD-d4, 400 MHz): δ = 7.77 (d, J = 7.5 Hz, 2H), 7.66
(d, J = 7.5 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.48–7.32 (m, 7H),
7.28 (dd, J = 7.5 Hz, 2H), 4.33 (m, 2H), 4.24–4.04 (m, 4H), 3.04
(m, 2H), 1.93 (m, 1H), 1.77 (m, 3H); 13C NMR (MeOD-d4,
100 MHz): δ = 175.4, 158.8, 145.2, 142.7, 131.4, 130.2, 128.9,
128.3, 126.3, 121.1, 68.1, 62.4, 57.1, 54.9, 48.5, 29.9, 23.0; MS
(ESI+) calcd for C27H29N3O4 [M + H]
+ 460.2, found 460.2.
(2S)-2-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-4-(piperidin-
1-yl)butanoic acid (4). The same procedure as for compounds
2. 95% yield; [α]20D = −11.3 (c = 0.8 in DMF); 1H NMR (MeOD-
d4, 400 MHz): δ = 7.79 (d, J = 7.5 Hz, 2H), 7.67 (d, J = 7.5 Hz,
1H), 7.65 (d, J = 7.5 Hz, 1H), 7.38 (dd, J = 7.5 Hz, 2H), 7.31
(dd, J = 7.5 Hz, 2H), 4.46–4.32 (m, 2H), 4.27 (m, 1H), 4.22 (t, J =
6.8 Hz, 1H), 3.50 (m, 2H), 3.19 (m, 1H), 3.12 (m, 1H), 2.91 (q,
J = 12.2 Hz, 2H), 2.35 (m, 1H), 2.15 (m, 1H), 1.90 (m, 2H), 1.80
(m, 3H), 1.50 (m, 1H); 13C NMR (MeOD-d4, 100 MHz): δ =
174.0, 158.8, 145.4, 142.7, 128.9, 128.3, 126.3, 121.1, 68.2, 55.5,
54.8, 54.5, 53.1, 27.4, 24.4, 22.7; HRMS (ESI+) calcd for
C24H28N2O4 [M + H]
+ 409.2122, found 409.2121.
(S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(piperidin-
1-yl)butanoic acid hydrochloride (7). The same procedure as
for compounds 2. 95% yield; [α]20D = +2.3 (c = 1.2 in DMF);
1H NMR (DMSO-d6, 400 MHz): δ = 7.94 (d, J = 7.5 Hz, 2H),
7.74 (dd, J = 7.5, 7.5 Hz, 2H), 7.69 (d, J = 8.2 Hz, 1H), 7.47
(dd, J = 7.5, 7.5 Hz, 2H), 7.37 (m, 2H), 4.42 (m, 1H), 4.31 (m,
3H), 3.45 (m, 2H), 3.21 (m, 2H), 2.96 (m, 2H), 2.73 (m, 2H),
2.01–1.62 (m, 5H), 1.42 (m, 1H); 13C NMR (DMSO-d6,
100 MHz): δ = 171.4, 155.5, 143.7, 140.7, 127.6, 127.0, 125.1,
120.1, 65.6, 58.4, 52.9, 51.9, 46.6, 43.6, 37.4, 21.9, 21.1; HRMS
(ESI+) calcd for C24H28N2O4 [M + H]
+ 409.2122, found
409.2123.
(S)-4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(piperidin-
1-yl)pentanoic acid hydrochloride (8). Same procedure than
for compounds 2. 84% yield; [α]20D = −1.7 (c = 1.1 in DMF);
1H NMR (DMSO-d6, 400 MHz): δ = 7.89 (d, J = 7.5 Hz, 2H), 7.70
(d, J = 7.5 Hz, 2H), 7.47 (d, J = 8.7 Hz, 1H), 7.41 (dd, J = 7.5,
7.5 Hz, 2H), 7.33 (dd, J = 7.5, 7.5 Hz, 2H), 4.45 (dd, J = 6.8,
10.4 Hz, 1H), 4.31 (m, 1H), 4.22 (t, J = 6.5 Hz, 1H), 3.89
(m, 1H), 3.37 (m, 2H), 3.10–2.92 (m, 2H), 2.86 (m, 2H), 2.21
(m, 2H), 1.77–1.46 (m, 7H), 1.35 (m, 1H); 13C NMR (DMSO-d6,
100 MHz): δ = 173.8, 155.8, 143.7, 140.7, 127.6, 127.0, 125.2,
120.1, 65.4, 58.7, 52.6, 51.9, 46.7, 45.7, 29.7, 28.1, 21.9, 21.21;
HRMS (ESI+) calcd for C25H30N2O4 [M + H]
+ 423.2278, found
423.2280.
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